United States · Bill · HR
H.R. 9297 (117th)
Pre-Approval Information Exchange Act of 2022
Introduced
15 November 2022
Last action
—
Status
Referred to the Subcommittee on Health.
Sponsors
—
Subjects
Discovery layer
Source updated
7 April 2025
Summary
Pre-Approval Information Exchange Act of 2022 This bill specifies that product information that is exchanged between drug manufacturers and certain health care entities (e.g., formulary committees) about drug products before regulatory approval is not considered to be misbranding if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 15 November 2022
Introduced in House (PDF)
Introduced in House · EN · 15 November 2022
Introduced in House
summary · EN · 15 November 2022
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/house-bill/9297
- Open data entity: https://api.congress.gov/v3/bill/117/hr/9297